Clinical Trial: Stress Management for Patients with Multiple Sclerosis

This study is currently recruiting patients.
Verified by National Institute of Child Health and Human Development (NICHD) September 2005

Sponsored by: National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier: NCT00147446

Purpose

There is a growing body of literature showing that stressful life events can increase the risk of developing exacerbations and new brain lesions among people with multiple sclerosis. The purpose of this study is to examine the hypothesis that stress management programs can reduce the occurrence of new brain lesions and exacerbations. We will also examine potential immune and neuroendocrine pathways.
Condition Intervention Phase
Multiple Sclerosis
 Behavior: Cognitive Behavioral Stress Management for MS
Phase II

MedlinePlus related topics:  Multiple Sclerosis

Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Dose Comparison, Parallel Assignment, Efficacy Study

Official Title: Phase II Study of the Effects of Stress Management on Neuroimaging, Clinical, Immune and Psychosocial Outcomes

Further Study Details: 
Primary Outcomes: MRI - acquired at baseline, and months 2, 4, 6, 8, 10, 12; Exacerbation rate based on patient report and verification by neurologist.; EDSS & MSFC at baseline, month 4, month 8 and month 12
Secondary Outcomes: Quality of Life at baseline, month 4, month 8 and month 12
Expected Total Enrollment:  120

Study start: May 2005

MS is a frequently disabling autoimmune disease affecting approximately 350,000 people in the United States. More than two decades of research has consistently shown a relationship between stressful life events (SLEs), in particular non-traumatic family and work stressors, and subsequent clinical exacerbation. Furthermore, we have shown that non-traumatic SLEs increase the risk of the subsequent appearance of new gadolinium enhancing (Gd+) magnetic resonance imaging (MRI) brain lesions, an early marker of MS inflammation and blood-brain barrier (BBB) breakdown. The purpose of this study is to determine the efficacy of cognitive behavioral stress management for MS (CBSM-MS) in reducing the occurrence of new brain lesions in people with relapsing forms of MS. Patients must have a documented new Gd+ MRI brain lesion or clinical exacerbation within the previous 12 months to be enrolled. One hundred and twelve patients will be enrolled for 12 months. Patients will be randomly assigned to either an intensive CBSM-MS program, consisting of 16 individual meetings with a behavioral medicine specialist, or a condensed CBSM-MS program, consisting of a one-day workshop offered after the 10th month of participation. Outcomes include MRI, clinical neurological end-points, and psychosocial functioning. We will also enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship between SLEs and clinical and neuroimaging markers of MS inflammation.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • Confirmed diagnosis of MS
  • New Gd+ MRI brain lesion or clinically diagnosed exacerbation within the previous 12 months.
  • Able to speak english.
  • Age 18 or over.
  • Able to give informed consent.
  • Patients taking the drug glatiramer acetate must have been on the drug for at least 6 months prior to their Gd+ MRI brain lesion and/or exacerbation.
  • Patients taking the and interferon beta drug must have been on the drug for at least 1 month prior to their Gd+ MRI brain lesion and/or exacerbation

Exclusion Criteria:

  • Meets criteria for dementia by scoring below the 5th percentile in 3 or more of 6 areas of neuropsychological functioning or as determined by study neuropsychologist.
  • Severe psychiatric pathology, including schizophrenia, bipolar disorder, current alcoholism or substance abuse, or other severe psychiatric disorder for which this intervention would be inappropriate.
  • Active and severe suicidal ideation.
  • Endocrine or metabolic disorder.
  • Currently in psychotherapy.
  • Initiated antidepressant therapy within the past 4 weeks.
  • Received corticosteroid treatment within the past 28 days.
  • Pregnant or planning pregnancy in the next 12 months.
  • Has any non-removable metal or medical device in the body for which an MRI could pose a danger.
  • Has an Expanded Disability Status Scale score greater than 6.5.
  • Recently begun relaxation, meditation, yoga, or similar form of disease management course within the past 3 months.
  • Treatment with Chemotherapy.

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00147446

Shiela Rosenthal, BA      800-923-1033    bmrc@itsa.ucsf.edu
Claudine Catledge, MA      415-221-4810  Ext. 4954    claudine.catledge@med.va.gov

California
      UCSF Behavioral Medicine Research Center, San Francisco,  California,  94121,  United States; Recruiting
Claudine Catledge, MA  415-221-4810  Ext. 4636    claudine.catledge@va.gov 
David C Mohr, Ph.D.,  Principal Investigator

Washington
      MS Hub, Seattle,  Washington,  United States; Recruiting
Yuriko Courtney  206-616-8967    nycourt@u.washington.edu 
Ted Brown, MD,  Principal Investigator

Study chairs or principal investigators

David C. Mohr, Ph.D.,  Principal Investigator,  University of California, San Francisco   
Claudine Catledge, MA,  Study Director,  San Francisco VAMC & Northern California Institute of Research and Education   

More Information

Website for the UCSF Behavioral Medicine Research Center

Study ID Numbers:  SIMS; R01 HD043323
Last Updated:  September 6, 2005
Record first received:  September 2, 2005
ClinicalTrials.gov Identifier:  NCT00147446
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-09-13

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us